A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
Public ClinicalTrials.gov record NCT04026997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Dose Response of Oral CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
Study identification
- NCT ID
- NCT04026997
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- CinDome Pharma, Inc.
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- CIN-102 Dose 1 Drug
- CIN-102 Dose 2 Drug
- CIN-102 Dose 3 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 10, 2019
- Primary completion
- Dec 16, 2020
- Completion
- Dec 16, 2020
- Last update posted
- Mar 24, 2026
2019 – 2020
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site 101 | Chula Vista | California | 91910 | — |
| Research Site 114 | Jacksonville | Florida | 32224 | — |
| Research Site 117 | Miami | Florida | 33134 | — |
| Research Site 118 | Miami | Florida | 33183 | — |
| Research Site 111 | Atlanta | Georgia | 30322 | — |
| Research Site 110 | Kansas City | Kansas | 66045 | — |
| Research Site 103 | Louisville | Kentucky | 40202 | — |
| Research Site 112 | Marrero | Louisiana | 70072 | — |
| Research Site 104 | Monroe | Louisiana | 71201 | — |
| Research Site 102 | Boston | Massachusetts | 02215 | — |
| Research Site 121 | Omaha | Nebraska | 68134 | — |
| Research Site 113 | Las Vegas | Nevada | 89123 | — |
| Research Site 109 | Great Neck | New York | 11023 | — |
| Research Site 120 | Winston-Salem | North Carolina | 27103 | — |
| Research Site 105 | Tulsa | Oklahoma | 74104 | — |
| Research Site 106 | Philadelphia | Pennsylvania | 19140 | — |
| Research Site 119 | Summerville | South Carolina | 29485 | — |
| Research Site 115 | Rapid City | South Dakota | 57702 | — |
| Research Site 107 | Jackson | Tennessee | 38305 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04026997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04026997 live on ClinicalTrials.gov.